Evaluation of Toxoplasma, Rubella, and Cytomegalovirus serological results in women of childbearing age

Fatma Avcioglu¹
Mustafa Behcet¹
Muhammet Guzel Kurtoglu¹

1. Department of Medical Microbiology, Abant Izzet Baysal University Faculty of Medicine, Bolu, Turkey.

http://dx.doi.org/10.1590/1806-9282.66.6.789

INTRODUCTION

Toxoplasma gondii, rubella, and cytomegalovirus (CMV) are microorganisms that can cause intrauterine infections and congenital anomalies in the fetus if they are transmitted during pregnancy¹. In developing countries, infections that cause congenital anomalies are one of the most predominant causes of perinatal morbidity and mortality². Toxoplasma gondii is a parasite that can cause hydrocephalus, intracranial calcifications, and chorioretinitis in fetus³. It is known as congenital toxoplasmosis if it is passed from mother to fetus during pregnancy³. Rubella is a virus that can cause congenital rubella infection, which can lead to low birth weight, deafness, myopia, cataracts, glaucoma, congenital heart disease, and intellectual disability in the fetus⁴. Finally, CMV is one of the largest viruses of the herpesviridae family, a common

SUMMARY

OBJECTIVE: This study aimed to determine the rates of IgG and IgM antibodies against cytomegalovirus, rubella, and Toxoplasma gondii (all of which may cause congenital infections) in women of childbearing age who were admitted to Bolu Abant İzzet Baysal University Training and Research Hospital.

METHODS: Between January 2015 and December 2017, Toxoplasma gondii, rubella, and cytomegalovirus IgM and IgG antibody levels were studied using the ELISA method (Architect i2000SR, Abbott, Germany) in patients aged 15 to 45 who attended the obstetrics and gynecology outpatient clinics. Toxoplasma gondii and cytomegalovirus IgG avidity levels were analyzed retrospectively.

RESULTS: A total of 13,470 tests were conducted in the laboratory. Seropositivity percentages of IgM antibodies were found to be 1.3%, 0.5%, and 1.6% for Toxoplasma (n = 3607), rubella (n = 3931), and cytomegalovirus (n = 3795), respectively. The seropositivity percentages of IgG antibodies were 22%, 94.2%, and 98.2% for Toxoplasma (n = 702), rubella (n = 693), and cytomegalovirus (n = 679), respectively. Primary infection (acute, recently acquired) was found in 7 (35%) patients with low Toxoplasma IgG avidity. One (3%) patient with low cytomegalovirus IgG avidity had a primary infection.

CONCLUSION: Toxoplasma gondii seronegativity was found to be high in the region. Therefore, screening women of childbearing age may be important for the prevention of congenital infections caused by Toxoplasma gondii.

KEYWORDS: Toxoplasma. Rubella. Cytomegalovirus. Immunoglobulin G. Immunoglobulin M.
used to determine whether the infection is primary (acute, recently acquired) or secondary (previously passed and immunized). In primary infections, the agent-specific IgG avidity is low, but in secondary infections it is high.

RESULTS

A total of 13,470 tests were conducted in the laboratory. Anti-Toxoplasma IgM was positive in 50 of the 3607 serum samples (1.3%) in which Toxoplasma IgM was examined. Anti-rubella IgM was found to be positive in 22 of 2231 serum samples (0.5%). Anti-CMV IgM was positive in 64 of 3795 serum samples (1.6%) of CMV IgM. Anti-CMV IgG was positive in 669 of 679 serum samples (98.2%) of CMV IgG. (Table 1).

Low avidity was detected in seven patients (35%) according to the avidity test performed on 20 patients with positive Toxoplasma IgM. High avidity was detected in eight patients (40%) according to the avidity test performed for Toxoplasma. One (3%) of the 33 patients with positive CMV IgM had low avidity. High avidity was detected in 32 patients (97%) according to the avidity test performed for CMV. Seropositivity rates for Toxoplasma (n = 702), rubella (n = 693), and CMV (n = 679) based on age group are shown in Table 2.

DISCUSSION

TORCH group infections can affect all age groups, but the transmission of these infections to the fetus during pregnancy is of growing concern, as these infections cause congenital anomalies in the fetus. Conducting these screening tests during pregnancy or early pregnancy contributes to the early diagnosis of congenital anomalies that may occur in the fetus and also determines the regional seroprevalence.

The seroprevalence of Toxoplasma gondii in the world may vary depending on a variety of factors, including dietary habits, lifestyle, socioeconomic

| Table 1. The Rates of IgM and IgG for Rubella, Toxoplasma Gondii, and Cytomegalovirus (CMV) Infections. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Test            | Negative (n %)  | Borderline (n %) | Positive (n %)  | Total           |
| Toxoplasma IgM  | 3544 (98.3)     | 13 (0.4)         | 50 (1.3)        | 3607            |
| Rubella IgM     | 3893 (99)       | 16 (0.4)         | 22 (0.5)        | 3931            |
| CMV IgM         | 3697 (97.5)     | 34 (0.9)         | 64 (1.6)        | 3795            |
| Toxoplasma IgG  | 538 (76.6)      | 9 (1.3)          | 155 (22.1)      | 702             |
| Rubella IgG     | 17 (2.4)        | 23 (3.3)         | 653 (94.2)      | 693             |
| CMV IgG         | 12 (1.8)        | 0                | 667 (98.2)      | 679             |
status, and geographical conditions\textsuperscript{11}. Some serological studies of \textit{Toxoplasma gondii} in Turkey and other countries are shown in Table 3\textsuperscript{12-18}. Indian studies have shown varied results, with seroprevalence ranging from 11% to 55%\textsuperscript{19}. In the present study, \textit{Toxoplasma} IgM was 1.3%, and \textit{Toxoplasma} IgG was 22%; these levels were lower than those found by the studies conducted abroad (especially in India and Saudi Arabia). In Turkey, \textit{Toxoplasma} IgM and IgG levels were similar, except for those found by the study in Kilis. The high seropositivity in the Kilis study may have been due to the consumption of undercooked meat and raw vegetables.

Rubella is a common viral infection that is frequently seen in children and young adults. In women of childbearing age, this infection is critical; it causes congenital rubella syndrome. In countries using the rubella vaccine (MMR) in their national vaccination programs, congenital rubella infections are less common\textsuperscript{20}. For example, in the routine vaccination program organized by the Ministry of Health in Turkey, rubella vaccination is performed in the first month of childhood and in the first grade of primary school. In studies conducted in different regions of Turkey, rubella seropositivity has been reported as ranging between 86.5% and 96.2\textsuperscript{11,19,21-23}. In the present study, the rate of rubella IgG was 94.2%. According to this ratio, and considering the fact that no vaccination information was obtained from the women of childbearing age, seronegativity has been found for women in Turkey. Therefore, vaccination will be beneficial, as these women are at risk for congenital rubella syndrome.

CMV can be transmitted via vertical and horizontal contact, blood transfusion, and organ transplants. Seroprevalence increases with age and differs according to geographical regions and socioeconomic level\textsuperscript{5}. While seropositivity rates in developed countries range from 50% to 60%, rates in developing countries are between 90% and 100\textsuperscript{21}. The results of serological studies of CMV in Turkey and other countries are shown in Table 4\textsuperscript{4,6,11,23}. In the present study, the rate

| TABLE 2. DISTRIBUTION OF TOXOPLASMOsis, CYtomegALOVIRUs (CMV), AND RUBEllA SEROPosITIVITY ACCORDING TO AGE GROUPS |
| Age (years) | Tox IgG (n = 702) | CMV IgG (n = 679) | Rubella IgG (n = 693) |
|------------|-----------------|------------------|----------------------|
| <20        | 4(28.6)         | 8(72.7)          | 8(88.9)              |
| 20-30      | 71(19.2)        | 346(99.9)        | 348(94.5)            |
| 31-40      | 75(24.4)        | 290(97.9)        | 280(92.7)            |
| >40        | 4(60)           | 23(100)          | 17(70.8)             |
| Total      | 155(38.6)       | 667(98.2)        | 653(94.2)            |

| TABLE 3. COMPARISON OF STUDIES EVALUATING TOXOPLASMA SEROPREVALENCES FROM DIFFERENT REGIONS OF TURKEY AND OTHER COUNTRIES. |
| Study      | Location, setting of the study | Test | Result(%) |
|-----------|--------------------------------|------|-----------|
| Sen et al.\textsuperscript{12} | India | Toxoplasma IgM | 19.4% |
| Yasodhara et al.\textsuperscript{13} | India | Toxoplasma IgM | 13.1% |
| Khurana et al.\textsuperscript{14} | India | Toxoplasma IgG, IgM | 15.3% IgG, 3% IgM |
| Ghazi et al.\textsuperscript{15} | Saudi Arabia | Toxoplasma IgG | 35.6% |
| Demiroğlu et al.\textsuperscript{16} | Kilis/Turkey | Toxoplasma IgG, IgM | 63.4% IgG, 4% IgM |
| Aşci et al.\textsuperscript{17} | Afyon/Turkey | Toxoplasma IgG, IgM | 23, 6% IgG, 19% IgM |
| Sirin et al.\textsuperscript{18} | Izmir/Turkey | Toxoplasma IgG, IgM | 32.3% IgG, 1.9% IgM |

| TABLE 4. COMPARISON OF STUDIES EVALUATING CMV SEROPREVALENCES FROM DIFFERENT REGIONS OF TURKEY |
| Study      | Location, setting of the study | Test | Result(%) |
|-----------|--------------------------------|------|-----------|
| Efe et al.\textsuperscript{4} | Van/Turkey | CMV IgG, IgM | 99.5% IgG, 1.7% IgM |
| Tamer et al.\textsuperscript{23} | Kocaeli/Turkey | CMV IgG, IgM | 96.4% IgG, 0.7% IgM |
| Ocak et al.\textsuperscript{19} | Hatay/Turkey | CMV IgG, IgM | 94.9% IgG, 0.4% IgM |
| Bakacakak et al.\textsuperscript{4} | Kahramanmaraş/Turkey | CMV IgG, IgM | 99.3% IgG, 3.2% IgM |
of CMV IgG was 98.2% and IgM was 1.6%. The highest CMV IgG results of studies conducted in Turkey was found by Efe et al. The high seropositivity in this study indicates that the risk of primary infection due to crowded living conditions in our region may be high. Therefore, screening CMV IgG and IgM antibodies in women of childbearing age will prevent the risk of CMV congenital infection in the future.

Avidity tests are used to differentiate whether an infection is a primary infection, re-infection, or secondary (pre-established and immunocompromised) infection. In primary infections, the specific IgG avidity (antigen-binding force) is low, while it is high in secondary infections. In this study, the number of positive patients with Toxoplasma IgM/G was 50, and the number of positive patients with CMV IgM/G was 64. However, the avidity test counts were 20 for Toxoplasma IgG avidity and 33 for CMV IgG avidity. In this study, Toxoplasma IgG was found to have a low avidity of 35%, and CMV IgG had a low avidity of 3%. In this study, low avidity detection in CMV IgG and Toxoplasma IgG avidity tests shows that there may still be acute CMV infections in our region. Therefore, it is important to evaluate avidity tests in women of childbearing age to differentiate between acute, past, and recurrent infections. Previous avidity studies in this country have been limited. Şimşek et al. found that Toxoplasma IgG avidity was 27% (low) and CMV IgG was 27% (low). In the present study, CMV IgG avidity values were lower, and Toxoplasma IgG avidity values were similar.

This study faced a few limitations. Toxoplasma, rubella, and CMV IgG and IgM test numbers were not studied equally. For example, the avidity IgG test was not studied in all patients with Toxoplasma and CMV IgG/M positivity. Another important limitation was that the vaccination history of the patients was unknown. In addition, the patients’ antibody levels were tested only at two years. The number of seropositive patients would have been higher if the study had been conducted over a longer period of time.

**CONCLUSION**

In conclusion, this screening could be an effective approach for women of childbearing age due to the high rate of Toxoplasma gondii seronegativity among women in Turkey. Finally, the high seroprevalence of these agents, in our society, calls for preventive strategies such as reproductive hygiene and immunization to circumvent the otherwise inevitable fetal outcomes. This study showed that the seropositivity of rubella and CMV are similar to the results found by other studies conducted in this country.

**Author contributions**

FA, MB collected the data; MB, MGK reviewed the literature; FA designed the study; FA wrote the manuscript; FA, MB, MGK approved the final version of the manuscript.
REFERENCES

1. Duran B, Toktasim A, Erden O, Demirel Y, Mamik AB, Cetin MA. Con- 
traversial issue in antenatal care: TORCH screening. Cumhuriyet Med J. 
2002;24:185-90.

2. Malayaloglu E. Perinatal infections. In: Bekasç M, Demir N, Koç A, Yükel 
A, eds. Obstetric maternal fetal medicine & perinatology. MN Medical & 
Nobel. 2001. p.470-523.

3. Madazlı R. Toxoplasma. In. Effective infectious diseases of fetus. Istanbul: 
Scala Publishing; 2000. p.213-61.

4. Efe S, Kurdoğlu Z, Korkmaz G. Seroprevalence of cytomegalovirus, rubella 
and toxoplasma antibodies in pregnant women of Van Region. Van Med J. 
2009;16:6-9.

5. Guclu E, Ince N. Cytomegalovirus infections. Türkiye Klinikleri J Inf Dis-Spe-
cial Topics; 2018;11(1):25-34.

6. Bakacak M, Bostancı MS, Köstü B, Erçan O, Senn S, Avcı F, et al. Seropreva-
lance of Toxoplasma gondii, rubella and cytomegalovirus among pregnant 
women. Dicle Medical Journal. 2014;41(2):326-31.

7. Binicker MI, Jespersen DJ, Harring JA. Multiplex detection of IgM and 
IgG class antibodies to Toxoplasma gondii, rubella virus, and Cytomeg-
lovirus using a novel multiplex flow immunoassay. Clin Vaccine Immunol. 
2010;17(11):1734-8.

8. Shashi C, Usha A, Aruna A. Prevalence of IgM antibodies to toxoplasma, 
rubella and Cytomegalovirus infections during pregnancy. Jk Science. 
2004;8:190-3.

9. Nimai K, Saha R, Ramachandran V, Khan A. TORCH infection in antenatal 
women: a 5-year hospital-based study. Eastern J Med Sci. 2019;2(4):54-7. 
[cited 2019 Dec 12]. Available from: https://atavarpub.net/EJMS/article/ 
view/671.

10. Sınmæk M, Kesli R, Demirci C, Çetinkaya Ö, Anıoz DT. Investigation seropreva-
lence of toxoplasma, rubella, cytomegalovirus and herpes simplex virus type 
2 in pregnant women followed in the Application and Research Hospital, 
Afyon Kocatepe University. Ortaçoglu Med J. 2016;8(1):1-6.

11. Öck S, Zeteroğlu S, Ozor C, Dolapçıoğlu K, Güngören A. Seroprevalence of 
Toxoplasma gondii, rubella and cytomegalovirus among pregnant women in 
southern Turkey. Scand J Infect Dis. 2007;39(3):231-4.

12. Sen MR, Shukla BN, Tuhina B. Prevalence of serum antibodies to TORCH 
infection in and around Varanasi, Northern India. J Clin Diagn Res. 
2012;6(9):1483-5.

13. Yasodhara P, Ramalakshmi BA, Naidu AN, Raman L. Prevalence of specific 
IGM due to toxoplasma, rubella, CMV and c.trachomatis infections during 
pregnancy. Indian J Med Microbiol. 2001;19(2):52-6.

14. Kurhane S, Bagga R, Aggarwal A, Lyngdoh V, Shivapiya, Diddi K, et al. 
Serological screening for antenatal toxoplasma infection in India. Indian J 
Med Microbiol. 2010;28(2):145-6.

15. Ghazi HO, Telmasian AM, Mahomed MF. TORCH agents in pregnant Saudi 
women. Med Princ Pract. 2002;11(4):180-2.

16. Demiröglu T, Akın Polat Z, Çelik C. Investigation of the risk factors affect-
ing Toxoplasma gondii seropositivity in women of reproductive age applic-
ing to the Maternity Clinic of Kilis State Hospital. Türkiye Parazitol Derg. 
2015;39(4):299-304.

17. Açlı Z, Akgün S. The evaluation of Toxoplasma gondii (T. gondii) serology 
results among cases who admitted to the serology laboratory of a hospital in 
Afsyn City. Türkiye Parazitol Derg. 2015;39(1):9-12.

18. Sirin MC, Aagus N, Yılmaz N, Bayram A, Denici YK, Samioglu P, et al. 
Seroprevalence of Toxoplasma gondii, rubella virus and cytomegalovirus 
among pregnant women and the importance of avidity assays. Saudi Med 
J. 2017;38(7):727-32.

19. Sirrupa P, Nibedita D, Pal D. Seroprevalence and risk factors of Toxo-
plasma gondii in pregnant women in Kolkata, India. J Recent Adv Appl 
Sci. 2011;16:27-33.

20. World Health Organization. Rubella. Geneva: World Health Organization; 
2019. [cited 2019 Dec 12]. Available from: https://www.who.int/en/news-
room/fact-sheets/detail/rubella#%20Accessed%20June%2022,%2020 
2019.

21. Parlak M, Çın N, Nalç Çerd B, Güven A, Bayram Y, Yıldızhan R. Seropreva-
lence of toxoplasma, rubella, and cytomegalovirus among pregnant women 
in Van. J Turk Soc Obstet Gynecol. 2015;30(2):79-82.

22. Karahulut A, Polat Y, Türk M, Isik Bali Y. Evaluation of rubella, Toxoplasma 
gondii, and cytomegalovirus seroprevalences among pregnant women in 
Denizli province. Turk J Med Sci. 2011;41:59-64.

23. Tamer GS, Dundar D, Caliskan E. Seroprevalence of Toxoplasma gondii, 
rubella and cytomegalovirus among pregnant women in western region of 
Turkey. Clin Invest Med. 2009;32(1):E43-7.

24. Us AD. Basic immunology and serology. General principles in serology. 
Ankara: Hippocrates Bookstore; 2016;106.